#ESCCongress | Estudo randomizado: inibição de SGLT2 reduziu o risco combinado de morte cardiovascular ou hospitalização em pacientes com insuficiência cardíaca e fração de ejeção preservada, independentemente da presença ou ausência de diabetes.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine

Comunicado de imprensa: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology

Comentário: Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction – EMPEROR-Preserved – American College of Cardiology

Comentário no Twitter

#FIGARO-DKD #ESCCongress
🔺in patients w T2D & microalbuminuria & stage 1-4 CKD, finerenone vs placebo led to 13% relative ⬇️in CV events (mostly due to 29%⬇️in HF hospitalizations)
🔺~2/3 pts +microalbuminuria w normal GFR:🔑 is to✔️in T2D#ESCCongress https://t.co/8oT5s8KjT0 pic.twitter.com/fQbmUzPasD

— Ritu Thamman MD (@iamritu) August 28, 2021